tylophorin
analog
raccryptopleurin
exhibit
potent
antihepat
c
viru
hcv
activ
alloster
regul
atpas
activ
heat
shock
cognat
protein
evalu
impact
modif
ere
raccryptopleurin
inhibitori
activ
hcv
replic
regul
atpas
activ
cryptopleurin
analog
group
maintain
activ
hcv
promot
atpadp
turnov
howev
compound
hydroxyl
group
posit
orient
exhibit
similar
activ
size
modif
heteroatom
incorpor
ere
led
loss
antihcv
activ
promot
chaperon
activ
carboxyl
terminu
interact
protein
chip
enhanc
antihcv
activ
raccryptopleurin
structureact
relationship
sar
studi
refin
structur
design
optim
develop
raccrytopleurin
analog
potent
antihcv
agent
target
host
factor
involv
hcv
replic
hepat
c
viru
hcv
infect
million
peopl
worldwid
approxim
hcv
infect
progress
chronic
diseas
includ
steatosi
cirrhosi
liver
cancer
standard
care
treatment
hcv
infect
includ
pegyl
interferona
ifna
ribavirin
ifnfre
directact
antivir
daa
agent
recent
use
daa
includ
proteas
inhibitor
polymeras
inhibitor
advanc
efficaci
antihcv
agent
almost
cure
hcv
genotyp
howev
daa
treatment
suitabl
patient
advanc
infect
high
risk
liver
failur
develop
hepatocellular
carcinoma
death
addit
patient
prior
histori
hepatocellular
carcinoma
treat
daa
hcv
infect
unexpect
high
recurr
rate
liver
cancer
previous
predict
recurr
rate
subgroup
addit
emerg
resist
high
cost
daa
treatment
still
high
barrier
hinder
broad
access
patient
addit
hcv
genomeencod
nonstructur
ns
protein
host
factor
play
essenti
function
everi
step
hcv
life
cycl
drug
target
host
factor
cellular
compon
function
involv
viral
life
cycl
emerg
new
therapeut
option
manag
hcv
infect
especi
potenti
agent
use
combin
daa
exampl
small
molecul
inhibitor
inhibit
peptidylprolyl
cistran
isomeras
activ
cyclophilin
suppress
replic
hcv
human
immunodefici
viru
hiv
coronavirus
previou
studi
suggest
heat
shock
cognat
protein
bind
untransl
region
ntr
involv
activ
hcv
replic
alloster
regul
atpas
activ
tylophorin
analog
raccryptopleurin
perturb
translat
hcv
rna
lead
inhibit
hcv
replic
raccryptopleurin
analog
exhibit
inhibitori
activ
sever
diseas
includ
cancer
arthriti
inflamm
dysenteri
design
synthes
seri
ere
modifi
raccryptopleurin
analog
show
improv
anticanc
activ
parent
compound
recent
report
tylophorin
analog
perturb
translat
hcv
rna
via
disrupt
replic
complex
especi
bind
hcv
rna
heat
shock
cognat
protein
despit
potenc
raccryptopleurin
exhibit
select
index
compound
hcv
replic
cytotox
low
ic
ec
fold
tabl
modif
ere
raccryptopleurin
also
chang
potenc
inhibitori
effect
nfjb
cre
signal
pathway
therefor
modif
ere
potenti
yield
compound
improv
pharmacolog
profil
raccryptopleurin
studi
determin
structuralact
relationship
sar
correl
ere
modifi
raccryptopleurin
analog
antihcv
activ
modul
chaperon
activ
aim
provid
insight
structur
could
modifi
design
new
compound
anti
hcv
activ
decreas
cytotox
previous
establish
relationship
anticanc
activ
protein
synthesi
inhibitori
effect
tylophorin
raccryptopleurin
analog
various
substitut
size
ere
studi
focus
effect
ere
modif
affect
antihcv
activ
modif
includ
addit
hydroxyl
group
differ
configur
ere
enlarg
ere
heteroatom
incorpor
ere
fig
antihcv
activ
determin
huhlucneoet
cell
harbor
hcv
genotyp
replicon
among
analog
compound
maintain
signific
antihcv
activ
ec
nm
compar
slightli
lower
raccryptopleurin
ec
nm
tabl
howev
select
ratio
hcv
activ
ec
cytotox
ic
increas
increas
ic
ec
ratio
tabl
chang
moieti
beta
alphaorient
led
significantli
decreas
antihcv
activ
cytotox
tabl
hand
chang
group
increas
antihcv
activ
cytotox
compar
incorpor
secondari
nitrogen
atom
oxygen
atom
sixmemb
ere
caus
signific
loss
antihcv
activ
tabl
presenc
tertiari
nitrogen
atom
substitut
dimethylamino
group
decreas
antihcv
activ
tabl
enlarg
sevenmemb
ere
contain
addit
carbon
oxygen
decreas
antihcv
activ
compar
raccryptopleurin
tabl
compound
fivememb
ere
essenti
lost
antihcv
activ
tabl
fact
antihcv
activ
exhibit
primarili
due
cellular
cytotox
consid
margin
differ
ec
ic
valu
low
ratio
ic
ec
tabl
activ
involv
replic
hcv
hepat
b
viru
hbv
ctermin
substrat
bind
domain
essenti
sequenc
replic
widetyp
lamivudineresist
hbv
reduc
replic
hbv
dna
result
decreas
express
level
caus
rna
interfer
treatment
natur
product
oxymatrin
analog
nsubstitut
matrin
acid
deriv
howev
cellular
machineri
requir
replic
hbv
partial
doubl
strand
dna
viru
distinct
hcv
treatment
raccryptopleurin
affect
express
level
h
fig
next
assess
antihbv
activ
cryptopleurin
analog
hbv
genomeintegr
cell
tabl
compound
ec
valu
hbv
higher
ec
valu
hcv
tabl
suggest
cryptopleurin
analog
specif
inhibit
hcv
replic
host
chaperon
protein
client
protein
activ
involv
viral
life
cycl
cyclophilin
cypa
directli
regul
hiv
infect
interact
ntermin
domain
capsid
protein
cypa
also
mediat
hcv
rna
bind
hcv
andstimul
replic
hcv
rna
coloc
hcv
particl
lipid
droplet
infect
cell
also
major
chaperon
protein
particip
assembl
sever
subcellular
complex
exampl
hcv
replic
complex
rnainduc
silenc
complex
chaperon
function
govern
ntermin
nucleotid
bind
domain
nbd
atpas
activ
mutat
atpas
pocket
abolish
chaperon
activ
bind
rna
promot
atpas
activ
raccryptopleurin
inhibit
hcv
thu
next
determin
impact
cryptopleurin
analog
atpadp
turnov
addit
raccryptopleurin
enhanc
adp
product
promot
atpas
activ
mm
fig
effect
atpas
activ
cryptopleurin
analog
examin
mm
fashion
raccryptopleurin
exhibit
similar
alloster
regul
fig
previous
raccryptopleurin
bound
physic
noncoval
nbd
therefor
function
analog
could
interfer
bind
raccryptopleurin
next
perform
affin
bind
assay
use
biotinylatedraccryptopleurin
elut
bound
affin
resin
raccryptopleurin
analog
elut
bound
affin
resin
similar
fashion
raccryptopleurin
fig
result
togeth
result
atp
adp
turnov
assay
suggest
cryptopleurin
deriv
function
analog
raccryptopleurin
similar
mechan
action
may
exhibit
antihcv
activ
mechan
rather
modul
atpas
activ
analog
lost
abil
modul
atpas
activ
fig
turnov
atpadp
primarili
govern
chaperon
activ
cochaperon
protein
nucleotid
exchang
factor
ctermin
cbag
increas
atpas
activ
combin
raccryptopleurin
determin
whether
raccryptopleurin
affect
luciferas
refold
activ
purifi
nativ
luciferas
first
denatur
guanidinehcl
incub
presenc
absenc
raccryptopleurin
luciferas
activ
determin
use
ml
aliquot
reaction
mixtur
specif
time
point
fig
luciferas
reactiv
increas
timead
dosedepend
manner
addit
mm
higher
concentr
raccryptopleurin
fig
fig
indic
compound
enhanc
chaperon
activ
carboxyl
terminu
interact
protein
chip
enhanc
protein
refold
activ
thu
promot
atp
hydrolysi
promot
degrad
heat
shock
protein
viral
coat
protein
complex
potato
viru
polymeras
complex
mump
viru
chip
regul
format
viral
replic
complex
viral
replic
accordingli
ad
recombin
chip
protein
luciferas
refold
reaction
system
recombin
chip
promot
luciferas
fold
fig
addit
chip
alon
margin
promot
luciferas
refold
activ
fig
howev
combin
chip
raccryptopleurin
promot
luciferas
refold
activ
fig
next
determin
whether
enhanc
chaperon
activ
relat
antihcv
activ
cryptopleurin
analog
transient
transfect
flagtag
chip
plasmid
empti
vector
ev
huhlucneoet
cell
cryptopleurin
analog
treatment
express
level
hcv
rna
protein
downregul
raccryptopleurin
fig
treatment
alon
fig
overexpress
chip
enhanc
inhibit
hcv
rna
protein
level
express
level
flagchip
chang
fig
b
result
suggest
stoichiometr
regul
cryptopleurin
analog
relat
antihcv
activ
studi
lai
et
al
exhibit
antitumor
activ
xenograft
model
abrog
autophagi
inhibitor
silenc
well
inhibit
protein
synthesi
proteasomedepend
degrad
previous
report
raccryptopleurin
inhibit
global
protein
synthesi
taken
togeth
result
suggest
function
analog
raccryptopleurin
could
use
scaffold
futur
design
cryptopleurin
analog
higher
potenc
hcv
increas
select
evalu
inhibitori
activ
cryptopleurin
analog
ere
modif
hcv
replic
cryptopleurin
analog
differ
hydroxyl
group
exhibit
improv
select
antihcv
activ
cytotox
analog
heteroatom
modif
ere
exhibit
cytotox
lost
antihcv
activ
select
increas
compar
raccryptopleurin
howev
effect
hcv
replic
atpas
promot
diminish
chang
size
ere
heteroatom
modif
led
total
loss
activ
among
cryptopleurin
analog
exhibit
similar
antihcv
activ
alloster
regul
atpas
activ
raccryptopleurin
well
select
hcv
hbv
fig
therefor
addit
raccryptopleurin
could
potenti
use
alon
combin
antihcv
regimen
highbarriertoresist
hcv
infect
tylophorin
analog
like
raccryptopleurin
inhibit
prolifer
cell
could
also
use
treatment
hcvassoci
hepatocellular
carcinoma
cell
cultur
media
fetal
bovin
serum
fb
purchas
invitrogen
waltham
usa
reagent
purchas
sigmaaldrich
st
loui
mo
usa
except
otherwis
note
yxm
compound
synthes
dr
kuohsiung
lee
laboratori
dissolv
dmso
lm
kept
stock
solut
hcv
genotyp
subgenom
replicon
cell
line
huhlucneoet
contain
luciferas
report
huh
provid
dr
ralf
bartenschlag
univers
heidelberg
huh
lucneoet
huh
cell
maintain
dmem
medium
suppli
fb
gibco
waltham
usa
mm
nonessenti
amino
acid
invitrogen
mgml
gibco
hepg
cell
cultur
meme
supplement
fc
gibco
lgml
kanamycin
cell
maintain
humidifi
co
atmospher
fireflyluciferas
report
activ
use
monitor
replic
hcv
replicon
huhlucneoet
cell
free
luciferas
activ
measur
luciferas
assay
kit
promega
madison
wisconsin
usa
spectramax
multimod
micropl
reader
molecular
devic
sunnyval
ca
usa
accord
manufactur
instruct
hbv
genom
integr
hepg
cell
seed
sixwel
cultur
plate
densiti
approxim
cell
per
well
cultur
medium
chang
everi
day
six
day
seed
cell
compound
ad
cell
cultur
fresh
medium
fed
everi
day
anoth
day
cell
collect
southern
analysi
viral
dna
total
dna
isol
use
dneasi
kit
qiagen
valencia
ca
usa
follow
manufactur
instruct
twenti
microgram
dna
separ
electrophoresi
agaros
transfer
hybondn
membran
amersham
bioscienc
buck
uk
use
capillari
transfer
method
ssc
overnight
uvcross
link
blot
prehybrid
mgml
salmon
sperm
dna
dilut
quickhyb
reagent
invitrogen
h
random
plabel
hbv
fulllength
probe
ad
prehybrid
reagent
hybrid
overnight
blot
wash
sd
twice
min
room
temperatur
sd
three
time
min
membran
expos
biomax
mr
film
kodak
rochest
ny
overnight
detect
use
phosphorimag
molecular
dynam
sunnyval
ca
usa
prepar
recombin
character
atp
hydrolysi
activ
perform
describ
previous
briefli
mm
incub
presenc
absenc
variou
mm
compound
atp
mm
hcv
widetyp
poli
uuc
rna
ml
reaction
buffer
mm
mop
ph
mm
mg
oac
mm
koac
mm
dtt
mgml
bsa
min
reaction
stop
ad
trichloroacet
acid
final
concentr
vv
aqueou
phase
wash
trioctylamin
vv
twice
concentr
adp
aqueou
phase
analyz
hplc
determin
standard
curv
gener
column
affin
purif
perform
describ
previous
huhlucneoet
cell
lyse
proteinbind
buffer
pbb
mm
hepe
ph
mm
nacl
mm
edta
nonidet
mm
mgcl
mm
complet
proteas
inhibitor
roch
biotinylatedraccryptopleurin
bound
overnight
room
temperatur
slurri
streptavidin
resin
invitrogen
buffer
contain
dmso
pbb
bead
wash
remov
unbound
compound
incub
recombin
bsa
bound
protein
wash
elut
raccryptopleurin
analog
sampl
separ
sd
page
examin
western
blot
cdna
chip
clone
use
forward
primer
revers
primer
insert
ndei
noti
restrict
enzym
site
vector
ctermin
histag
recombin
protein
overproduc
e
coli
plyss
cell
promega
madison
wi
h
purifi
ni
nta
agaros
qiagen
valencia
ca
dialyz
mm
hepeskoh
ph
contain
mm
potassium
chlorid
mm
dtt
vv
glycerol
refold
chemic
denatur
firefli
luciferas
presenc
absenc
tylophorin
analog
measur
describ
previous
briefli
luciferas
dilut
denatur
buffer
mm
hepe
ph
mm
kcl
mm
mgcl
guanidinehcl
mm
dtt
final
concentr
mm
denatur
reaction
allow
proceed
min
ml
aliquot
remov
mix
ml
refold
buffer
mm
hepe
ph
mm
kcl
mm
mgcl
mm
atp
supplement
mm
presenc
absenc
raccryptopleurin
presenc
absenc
recombin
chip
refold
reaction
incub
aliquot
ml
remov
fold
reaction
indic
time
luciferas
activ
measur
data
analyz
twotail
student
ttest
use
prism
graph
pad
differ
consid
statist
signific
p
